Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Impact and prognosis of pembrolizumab combination in neoadjuvant chemotherapy for triple-negative breast cancer: A single-center retrospective study.

Tomomi Fujisawa, Takeshi Miyamoto, Shoko Tokuda et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12507

e12507 Background: The addition of pembrolizumab (PEM) to neoadjuvant chemotherapy (NAC) has been shown to significantly i...

Lung cancer stage prediction using longitudinal CT imaging compared with single-timepoint assessment.

Amrik Majumdar, Michael E. Bryan Jun 01, 2026 pp. 8018-8018 10.1200/jco.2026.44.16_suppl.8018

8018 Background: Lung cancer staging guides treatment decisions but is based on single-timepoint imaging, treating tumors...

Change in relative cerebral blood volume as a biomarker for early response to bevacizumab in patients with recurrent glioblastoma: ECOG-ACRIN EAF151.

Jerrold L. Boxerman, Bradley S. Snyder, Kathleen M. Schmainda et al. Jun 01, 2026 pp. 2016-2016 10.1200/jco.2026.44.16_suppl.2016

2016 Background: Bevacizumab therapy (Bev) for recurrent glioblastoma (rGBM) has not demonstrated improved overall surviva...

Spatial multiomic profiling to identify de-differentiated tumor phenotypes and exhausted T cell niches in rhabdoid and sarcomatoid RCC.

Zachary Alan Yochum, Sayed Matar, Peter Humphrey et al. Jun 01, 2026 pp. 4557-4557 10.1200/jco.2026.44.16_suppl.4557

4557 Background: Rhabdoid and sarcomatoid (S/R) differentiation are high-grade dedifferentiated states that can arise acro...

Disparities in race and insurance status among hospitalized patients with pancreatic cancer and protein–energy malnutrition: A nationwide analysis, 2016–2022.

Alexandra Sueldo, Dileep Kumar Reddy Regalla, Lucas Kuzmanic et al. Jun 01, 2026 pp. 11052-11052 10.1200/jco.2026.44.16_suppl.11052

11052 Background: Protein–energy malnutrition (PEM) is frequently encountered in patients with pancreatic cancer and is as...

Effects of upfront dual immunotherapy on overall survival in patients with metastatic non-small cell lung cancer with no targetable mutations or PD-L1 expression.

Esteban Toro Velez, Carolina Velez-Mejia, Andrew Stewart Poklepovic et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20588

e20588 Background: Upfront treatment decision for patients with metastatic Non-Small Cell Lung Cancer (NSCLC) with no targ...

Assessing breast density: Are convolutional neural networks the only path?

Anxhelo Shehu, Kleida Mati, Renè Natowicz Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12558

e12558 Background: Beyond reducing image interpretability, high breast density is an independent risk factor for breast ca...

Impact of Medicaid expansion on five-year mortality among patients with melanoma in the United States.

Oladayo Oyebanji, Akachukwu Eze, Mojisola Fasokun et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21603

e21603 Background: Melanoma survival depends on early diagnosis and timely access to definitive surgery and modern systemi...

A phase 3 randomized, open-label study of pasritamig (JNJ-78278343), a T-cell engager targeting human kallikrein-2, with docetaxel versus docetaxel for metastatic castration-resistant prostate cancer.

Rana R. McKay, Kai-Jie Yu, Teresa Alonso Gordoa et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps5139

TPS5139 Background: Metastatic castration-resistant prostate cancer (mCRPC) remains an incurable disease with high morbidi...

Treatment selection for first- and second-line therapy and survival outcomes in advanced biliary tract cancer: A large real-world retrospective analysis.

Yiwen Zhou, Haimin Weng, Wangye Zheng et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16197

e16197 Background: Biliary tract cancer (BTC) is an aggressive malignancy with constrained therapeutic options. This study...

Postoperative adjuvant donafenib-based therapy for patients with hepatocellular carcinoma at high risk of recurrence.

Yang Wang, Xiao Chen, Ronghai Huang Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16256

e16256 Background: The 5-year recurrence rate after radical resection for hepatocellular carcinoma (HCC) is as high as 70%...

National burden of cholangiocarcinoma in the United States: A 20-year analysis of temporal trends and racial disparities (2005–2024).

Rishi Chowdhary, Kirti Arora, Abdulfatah Issak Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16493

e16493 Background: Cholangiocarcinoma (CCA) is an uncommon but highly lethal malignancy with rising global concern, yet lo...

Neoadjuvant immunotherapy combined with concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A prospective, single-arm, phase II trial.

Weiwei Wang, Jia He, Junfang Yan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16095

e16095 Background: Concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced esophageal squamous...

Interim analysis of TAD: A phase 2 single-arm open-label study of combination therapy of transarterial chemoembolization and ablation with durvalumab in unresectable hepatocellular carcinoma.

Zhenggang Ren, Jia Yuan, Bei Tang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16296

e16296 Background: Transarterial chemoembolization (TACE) combined with ablation has been used to treat unresectable hepat...

Inferring molecular signatures in colorectal cancer directly from routine whole-slide images.

Piotr Keller, Mark Eastwood, Gertjan Rasschaert et al. Jun 01, 2026 pp. 3522-3522 10.1200/jco.2026.44.16_suppl.3522

3522 Background: Molecular profiling has advanced colorectal cancer (CRC) research but remains limited in the clinic due t...

Gaps in patient-facing information on artificial intelligence in cancer care: A cross-sectional analysis.

Pearl Subramanian, Suditi Shyamsunder, Khashayar Eshaghi et al. Jun 01, 2026 pp. 9000-9000 10.1200/jco.2026.44.16_suppl.9000

9000 Background: Artificial intelligence (AI) is increasingly integrated into cancer care and is also widely acces...

Impact of CAPOX combined with traditional Chinese medicine (TiaoPi AnChang Decoction) on disease-free survival in patients with stage III or high-risk stage II colorectal cancer: An updated report of a randomized, double-blind, placebo-controlled trial.

Jincheng Zhang, Zhiqiang Cheng, Jianzheng Jie et al. Jun 01, 2026 pp. 3645-3645 10.1200/jco.2026.44.16_suppl.3645

3645 Background: Colorectal cancer (CRC) at early and mid-stages has significantly different prognoses from advanced CRC....

Targeted sensorimotor training vs. general aerobic exercise for chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.

Aakash Pandit, Melisha Koirala Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24175

e24175 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity in breast cancer patients...

Real-world comparison of enzalutamide and darolutamide for non-metastatic castration-resistant prostate cancer: A multicenter retrospective study.

Naoki Fujita, Yohei Kawashima, Masanao Shinohara et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17048

e17048 Background: Although enzalutamide and darolutamide share a common mechanism of action targeting the androgen recept...

Knowledge, attitude, and practices of residents towards venous thromboembolism prophylaxis among cancer patients at Quirino Memorial Medical Center.

Orlando Jr Kawis, Nunilon Gallardo Vergara Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22552

e22552 Background: The risk of venous thromboembolism (VTE) is higher in individuals with cancer than in those without can...

Fern-EC-01 (BNT323-01): A phase 3 trial of trastuzumab pamirtecan (HER2 ADC) versus investigator’s choice of chemotherapy in patients with previously treated, HER2-expressing, recurrent endometrial cancer (EC).

Floor Jenniskens Backes, John McGrane, Bhavana Pothuri et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps5645

TPS5645 Background: Despite advancements in frontline therapies for EC, treatment options for recurrent/refractory disease...

Updated efficacy and safety of first-line PD-1 inhibitors plus metronomic oral vinorelbine in elderly patients with advanced NSCLC.

Lin Li, Siqi Zhang, Yue Yuan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20590

e20590 Background: Elderly patients (≥70 years) with metastatic non-small cell lung cancer (NSCLC) face challenges with st...

Beyond survival: Longitudinal prognostication in glioblastoma using conditional survival—A population-based study.

Obuli Srinivasan Gurunathan, Owais Gul, Fawad Talat et al. Jun 01, 2026 pp. 2045-2045 10.1200/jco.2026.44.16_suppl.2045

2045 Background: Glioblastoma multiforme (GBM) carries a poor prognosis, and the initial survival projections provided at...

Clinicopathological analysis and therapeutic management of radiation-induced sarcomas of the head and neck: A single-center retrospective study.

Xin Liu, Yanjing Guo, ShiWen Zhuang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23537

e23537 Background: Radiation-induced sarcoma of the head and neck (RISHN) is a rare but devastating late toxicity of curat...

Clinical and genetic landscape of individuals evaluated in a CHIP cardiology clinic: A single-center experience, 2020 to 2025.

Ohad Oren, Nicholas Chiu, Aeron Small et al. Jun 01, 2026 pp. 6593-6593 10.1200/jco.2026.44.16_suppl.6593

6593 Background: Despite growing observational data linking clonal hematopoiesis of indeterminate potential (CHIP) to adve...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page